Skip to main content
OpenTrials
Completed

NCT Number: NCT04893837

Non-Invasive Monitoring of Traumatic Brain Injury Progression Using the Infrascanner (MOBI-1)

MOBI-1 is a multicenter clinical trial that will evaluate the use of the Infrascanner for the monitoring of traumatic intracranial hematomas.

Completed

Looking for future studies?

Notify Me

Key information

About this study

MOBI-1 is a single-arm, multi-center derivation / validation study that will evaluate the use of the Infrascanner for monitoring traumatic intracranial hematomas. All patients will receive standard care plus hourly infrascanner assessments. This study will test the hypotheses that:

  • The Infrascanner has sufficient diagnostic performance to detect the expansion of intracranial hematomas
  • Patients who have expanding intracranial hematomas will be identified faster when monitored with hourly infrascanner assessments compared to standard care alone
  • Clinical / research staff will be able to attain all data points and relay the assessments to the medical team.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 15 or older
  • Admission CT Scan shows intracranial hemorrhage
  • Glasgow Coma Scale less than 15
  • Neurosurgery service determines initial care is nonoperative
  • Admitted for observation for TBI, to either step-down unit or intensive care unit

Exclusion criteria

  • Inability to provide informed consent or lack of a legally authorized representative (LAR)
  • Admitted and observed for >2 hours prior to screening (i.e., has already received second neurological check)
  • Other injuries deemed non-survivable
  • Diagnosed with hemorrhagic shock or receives a large volume transfusion (>3 units of any blood product within any 1 hour)
  • Planned surgical interventions/ procedures during study period (before the second CT scan)
  • Known prisoner

Treatment and study plan

Standard care plus infrascans

Device

Hourly infrascans to detect expanding intracranial hematomas

Primary outcomes

  1. Diagnostic performance of the infrascanner

    Time frame: Month 24

    Number of participants whose Infrascan results were accurate

Secondary outcomes

  1. Time to detection of an enlarging hematoma

    Time frame: 0-12 hours

    Difference in time to detection of hematoma enlargement between Infrascan and second CT across the cohort

Sponsors and collaborators

Lead sponsor

University of Alabama at Birmingham

Other

Collaborators

  • InfraScan, Inc.
  • United States Department of Defense

Registry information

Acronym: MOBI-1

Important dates

Study start
2022
Primary completion
2025
Study completion
2025
First posted
May 20, 2021
Registry last updated
Sep 2, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.